DEA Temporarily Places Mitragynine Pseudoindoxyl, MGM-15 and MGM-16 in Schedule I

Why it matters

The order changes the legal status of three potent, kratom-related synthetic opioids and affects possession, distribution, research and analysis. It also gives clinicians, laboratories and policymakers a clear federal reference for distinguishing these compounds from plant kratom.

The big picture

DEA says these substances emerged from chemical modifications of mitragynine or 7-hydroxymitragynine and have appeared in consumer products. The temporary action lasts two years, with a possible one-year extension, while permanent scheduling procedures may proceed.

Key findings

• The substances are mitragynine pseudoindoxyl, MGM-15 and MGM-16, including specified isomers, esters, ethers and salts
• The order becomes effective upon Federal Register publication and remains in force through August 26, 2028, unless extended or made permanent
• DEA cites high abuse potential, no accepted medical use in the United States and inadequate safety under medical supervision
• The agency reports strong mu-opioid receptor activity and preclinical analgesic potency, alongside dependence and respiratory-depression risks
• The order imposes Schedule I controls on handling, import, export, research, analysis and possession

What they say

DEA states that uncontrolled manufacture, distribution, possession and abuse of the three substances pose an imminent hazard to public safety.

Bottom line

**The federal order targets three synthetic 7-hydroxymitragynine-related opioids, not naturally occurring kratom leaf itself.**